Biochemical markers of bone turnover and bone mineral density in patients with β-thalassaemia major

International Journal of Clinical Practice

Volumn 59, Issue 1, 2005, Pages 46-51

  Eren, E ^a   Yilmaz, Necat ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Bone mineral density; Deoxypyridinoline; Osteocalcin; Thalassaemia major

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; OSTEOCALCIN; PARATHYROID HORMONE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ELECTROIMMUNOASSAY; FEMALE; FEMUR NECK; GROUPS BY AGE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THALASSEMIA MAJOR;

ADULT; ALKALINE PHOSPHATASE; AMINO ACIDS; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; BONE REMODELING; CHILD; DENSITOMETRY, X-RAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; OSTEOCALCIN; OSTEOPOROSIS;

EID: 13844319576     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2005.00358.x     Document Type: Article

References (14)

1. Yilmaz N, Bayram M, Erbagci AB, Kilincer S. Diagnostic value of biochemical markers of bone turnover and postmenopausal osteoporosis. Clin Chem Lab Med 1999; 37 (2): 137-43.
2. Yilmaz N, Pence S, Kepekci Y, Geyikli I, Ozaslan J. Association of immune function with bone mineral density and biochemical markers of bone turnover in patients with ankylosing spondylitis. Int J Clin Pract 2003; 57 (8): 681-5.
3. Yilmaz N, Ozaslan J. Biochemical bone turnover markers in patients with ankylosing spondylitis. Clin Rheumatol 2000; 19 92-8.
4. Molyvda-Athanasopoulou E, Sioundas A, Karatzas N, Aggellaki M, Pazaitou K, Vainas I. Bone mineral density of patients with thalassaemia major: four-year follow-up. Calcif Tissue Int 1999; 64: 481-4.
5. Marabito N, Lasco A, Gaudio A et al. Bisphosphonates in the treatment of talassaemia-induced osteoporosis. Osteoporos Int 2002; 13: 644-9.
6. Dresner Pollak R, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with β-thalassaemia major and intermedia. Br J Haematol 2000; 111: 902-7.
7. Voskaridou E, Kyrtsonis MC, Terpos E et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 2001; 112: 36-41.
8. Di Stefano M, Chiabotto P, Roggia C et al. Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. J Bone Miner Metab 2004; 22: 53-7.
9. Buchowsky MS, De La Fuente FA, Flakoll PJ, Chen KY, Turner EA. Increased bone turnover is associated with protein and energy metabolism in adolescents with sickle cell anemia. Am J Physiol Endocrinol Metab 2001; 280: 518-27.
10. Mahachoklertwattana P, Chuansumrit A, Sirisriro R, Choubtum L, Sriphradang A, Rajatanavin R. Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with β-thalassaemia disease. Clin Endocrinol 2003; 58: 273-9.
11. Voskaridou E, Terpos E, Spina G et al. Pamidronate is an effective treatment for osteoporosis in patients with β -thalassaemia. Br J Haematol 2003; 123: 730-7.
12. Mahachoklertwattana P, Chuansumrit A, Choubtum L, Sriphradang A, Sirisriro R, Rajatanavin R. Bone mineral density in children and young adults with β-thalassaemia trait. J Pediatr Endocrinol Metab 2002; 15 (9): 1531-5.
13. Jensen CE, Tuck SM, Agnew JE et al. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998; 103: 911-5.
14. Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Semin Hematol 1995; 32 (4): 304-12.